MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3324/haematol.2022.281242

Медицинская библиотека · Haematologica · 2023

Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.

Zurko Joanna, Ramdial Jeremy, Shadman Mazyar, Ahmed Sairah, Szabo Aniko, Iovino Lorenzo, Tomas Ana Alarcon, Sauter Craig, Perales Miguel-Angel, Shah Nirav N, Acharya Utkarsh H, Jacobson Caron, Soiffer Robert J, Wang Trent, Komanduri Krishna V, Jaglowski Samantha, Kittai Adam S, Denlinger Nathan, Iqbal Madiha, Kharfan-Dabaja Mohamed A, Ayala Ernesto, Chavez Julio, Jain Michael, Locke Frederick L, Samara Yazeed, Budde Lihua E, Mei Matthew G, Pia Alexandra Della, Feldman Tatyana, Ahmed Nausheen, Jacobs Ryan, Ghosh Nilanjan, Dholaria Bhagirathbhai, Oluwole Olalekan O, Hess Brian, Hassan Ayesha, Kenkre Vaishalee P, Reagan Patrick, Awan Farrukh, Nieto Yago, Hamadani Mehdi, Herrera Alex F

Многоцентровое исследованиеСтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Allogeneic hematopoietic cell transplantation (alloHCT) can potentially salvage large B-cell lymphoma (LBCL) patients experiencing treatment failure after chimeric antigen receptor T-cell therapy (CAR T). Nonetheless, data on the efficacy and toxicities of alloHCT after receipt of CAR T are limited. We report a multicenter retrospective study assessing the safety, toxicities, and outcomes of alloHCT in LBCL patients following CAR T failure. Eighty-eight patients with relapsed, refractory LBCL received an alloHCT following anti-CD19 CAR T failure. The median number of lines of therapy between CAR T infusion and alloHCT was one (range, 0-7). Low intensity conditioning was used in 77% (n=68) and peripheral blood was the most common graft source (86%, n=76). The most common donor types were matched unrelated donor (39%), followed by haploidentical (30%) and matched related donor (26%). Median follow-up of survivors was 15 months (range, 1-72). One-year overall survival, progression-free survival, and graft-versus-host disease-free relapse-free survival were 59%, 45%, and 39% respectively. One-year non-relapse mortality and progression/relapse were 22% and 33% respectively. On multivariate analysis, <2 lines of intervening therapy between CAR T and alloHCT and complete response at time of alloHCT were associated with better outcomes. In conclusion, alloHCT after CAR T failure can provide durable remissions in a subset of patients.

Для цитирования: Zurko Joanna, Ramdial Jeremy, Shadman Mazyar, Ahmed Sairah, Szabo Aniko, Iovino Lorenzo, Tomas Ana Alarcon, Sauter Craig, Perales Miguel-Angel, Shah Nirav N, Acharya Utkarsh H, Jacobson Caron, Soiffer Robert J, Wang Trent, Komanduri Krishna V, Jaglowski Samantha, Kittai Adam S, Denlinger Nathan, Iqbal Madiha, Kharfan-Dabaja Mohamed A, Ayala Ernesto, Chavez Julio, Jain Michael, Locke Frederick L, Samara Yazeed, Budde Lihua E, Mei Matthew G, Pia Alexandra Della, Feldman Tatyana, Ahmed Nausheen, Jacobs Ryan, Ghosh Nilanjan, Dholaria Bhagirathbhai, Oluwole Olalekan O, Hess Brian, Hassan Ayesha, Kenkre Vaishalee P, Reagan Patrick, Awan Farrukh, Nieto Yago, Hamadani Mehdi, Herrera Alex F. Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.. Haematologica. 2023. DOI: 10.3324/haematol.2022.281242.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.